MYC dysregulation is implicated in the onset and progression of several hematological malignancies, and its involvement ranges from being disease-defining, as in Burkitt’s lymphoma [30], to cases where increased MYC expression, by means of deregulation or amplification events, is correlated with an inferior clinical outcome [1]. This evidence concerns the gene MYC and hematologic disorder.